Bupropion versus placebo All biochemically validated · smokers with current depression
Bupropion showed no clear difference in bupropion versus placebo All biochemically validated compared with control (low certainty).
1 finding from 1 review
Bupropion versus placebo Biochemical validation (majority) and self report · patients with smokers with past depression
Bupropion may leads to higher bupropion versus placebo Biochemical validation (majority) and self… compared with control (low certainty).
1 finding from 1 review
Smoking cessation · people who smoke
Bupropion leads to higher smoking cessation (at least six months of compared with placebo/no pharmacological treatment (high certainty).
1 finding from 1 review
Serious adverse events · people who smoke
Bupropion showed no clear difference in serious adverse events compared with placebo/no pharmacological treatment (moderate certainty).
1 finding from 1 review
Dropouts due to treatment · people who smoke
Bupropion leads to higher dropouts due to treatment compared with placebo/no pharmacological treatment (high certainty).
1 finding from 1 review
Biochemically validated smoking cessation at the latest point in pregnancy (20 weeks' gestation or more) · Pregnant women who smoke
Bupropion showed no clear difference in biochemically validated smoking cessation at the latest point in… compared with control (low certainty).
1 finding from 1 review
Mean birthweight · Pregnant women who smoke
Bupropion showed no clear difference in mean birthweight (g) compared with control (low certainty).
1 finding from 1 review
Miscarriage and spontaneous abortion · Pregnant women who smoke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endpoint scale total scores (150 mg twice daily dose) (Scales of sexual functioning. As studies used different scales to assess sexual functioning, differences are expressed as standardised mean differences (SMD)) · people with antidepressant‐induced sexual dysfunction
1 finding from 1 review
Effect on later sexual function · people with antidepressant‐induced sexual dysfunction
Bupropion showed no clear difference in 50% reduction in score on the Arizona Sexual Experiences Scale… compared with placebo (moderate certainty).
1 finding from 1 review
Dropout · people with antidepressant‐induced sexual dysfunction
Bupropion showed no clear difference in dropouts (People leaving the trial early) compared with placebo (high certainty).
1 finding from 1 review
Incidence of SAD (SIGH‐SAD score ≥ 20) ( · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL probably leads to lower incidence of SAD (SIGH‐SAD score ≥ 20) compared with placebo (moderate certainty).
1 finding from 1 review
Overall rate of adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in overall rate of adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Headache · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL probably leads to higher headache compared with placebo (moderate certainty).
1 finding from 1 review
Insomnia · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL may leads to higher insomnia compared with placebo (low certainty).
1 finding from 1 review
Nausea · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL may leads to higher nausea compared with placebo (low certainty).
1 finding from 1 review
Diarrhoea · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in diarrhoea compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in discontinuation due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Total mortality · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in total mortality compared with placebo (moderate certainty).
1 finding from 1 review
Cardiovascular morbidity · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in cardiovascular morbidity compared with placebo (low certainty).
1 finding from 1 review